ABPO.US Abpro Holdings, Inc.
- Market cap
- USD 3.01M
- P/E
- 0.3x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ABPO.US undervalued?
Graham numberThe Graham number of Abpro Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abpro Holdings, Inc. fundamental analysis
No fundamental analysis for Abpro Holdings, Inc. yet.
Abpro Holdings, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides flexibility to combine antibody b…
Full company profileAbpro Holdings, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abpro Holdings, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.03M | 122K | 183K | 0.00 | 0.00 |
| Operating Income | -16.7M | -11.7M | -9.92M | -4.05M | -4.22M |
| EBITDA | -15.8M | -10.9M | -5.82M | -225K | -3.83M |
| Net Income | -17.2M | -11.7M | -7.23M | -2.89M | -3.94M |
| EPS | -0.34 | -0.23 | -0.14 | -1.06 | -0.67 |
| Balance Sheet | |||||
| Total Assets | 11.9M | 3.36M | 4.66M | 1.06M | 5.24M |
| Total Liabilities | 87.6M | 91.8M | 19.6M | 9.35M | 8.23M |
| Shareholders' Equity | -76.3M | -89.0M | -15.5M | -8.83M | -3.53M |
| Cash & Short-term Investments | 7.33M | 723K | 2.85M | 67.0K | 4.24M |
| Cash Flow | |||||
| Operating Cash Flow | -8.95M | -7.40M | -9.03M | -6.01M | -6.27M |
| Capital Expenditure | 65.0K | 48.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -9.02M | -7.45M | -9.03M | -6.01M | -6.27M |
| Ratios | |||||
| ROA | -145.2% | -348.9% | -155.2% | -272.1% | -75.1% |
| Net Profit Margin | -848.4% | -9,595.1% | -3,951.9% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Abpro Holdings, Inc. dividends
Abpro Holdings, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:30 on Nov 3, 2025.
Who owns Abpro Holdings, Inc.
- Insiders 16.09%
- Institutions 0.01%
- Public & others 83.90%
- Shares outstanding 5.90M
- Free float 4.95M
Abpro Holdings, Inc. company profile
- Company name
- Abpro Holdings, Inc.
- Ticker
- ABPO.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 100 Summit Drive, Burlington, MA, United States, 01803
- Phone
- 339 227 5961
- Website
- abpro.co
About Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides flexibility to combine antibody building blocks in different combinations and orientations to create fit-for-purpose novel full-length multispecific antibody constructs. The company's lead product candidates include ABP-102, a next-generation immuno-oncology TetraBi antibody targeting HER2 and CD3 developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibits VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Abpro Holdings, Inc. management
2- Mr. M. Fathi KaratasInterim CEO & Director · born 1979
- Mr. Eugene Y. Chan M.D.Co-Founder · born 1975